Octreotide Improved Ventricular Arrhythmia in an Acromegalic Patient.

Accession number;00A0416118
Title;Octreotide Improved Ventricular Arrhythmia in an Acromegalic Patient.
Author; SUYAMA K (Chiba Univ. School Of Medicine, Chiba, Jpn) UCHIDA D (Chiba Univ. School Of Medicine, Chiba, Jpn) TANAKA T (Chiba Univ. School Of Medicine, Chiba, Jpn) SAITO J (Chiba Univ. School Of Medicine, Chiba, Jpn) NOGUCHI Y (Chiba Univ. School Of Medicine, Chiba, Jpn) NAKAMURA S (Chiba Univ. School Of Medicine, Chiba, Jpn) TASUNO I (Chiba Univ. School Of Medicine, Chiba, Jpn) SAITO Y (Chiba Univ. School Of Medicine, Chiba, Jpn) SAEKI N (Chiba Univ. School Of Medicine, Chiba, Jpn)
Journal Title;Endocr J
Journal Code:F0625A
ISSN:0918-8959
VOL.47;NO.Supplement;PAGE.S73-S75(2000)
Figure&Table&Reference;FIG.1, TBL.1, REF.6
Pub. Country;Japan
Language;English
Abstract;We saw a remarkable effect of octreotide, the long-acting somatostatin analogue, in reducing the number of ventricular premature complexes (VPCs) in a 59-year-old woman with acromegaly. Her basal GH and IGF-1 levels were up to 22.9ng/ml and 934.9ng/ml respectively. MRI revealed a 14*12*10mm mass lesion in the pituitary gland. She had hypertension and echocardiography showed an increase in left ventricular wall thickness. Electric cardiography showed the presence of frequent VPCs and 24-h Holter monitoring revealed 24277 beats of multifocal VPCs/24h. She was treated with 300.MU.g/day of octreotide for four weeks before transsphenoidal surgery. After octreotide treatment, GH and IGF-1 were suppressed to 1.8ng/ml and 145.3ng/ml respectively, and the tumor size was remarkably reduced. Furthermore, the number of VPCs was also dramatically reduced to 2062 VPCs/24-h (8.5% of pretreatment) with 24-h Holter monitoring. This case shows that VPCs of acromegalic patients can be controlled by suppressing GH and IGF-1 with octreotide, and this agent is useful for reducing both tumor size and frequency of VPCs prior to surgery. (author abst.)
Related Articles;
Loading...
FULLTEXT